Retirement Systems of Alabama purchased a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) during the 3rd quarter, Holdings Channel reports. The institutional investor purchased 98,117 shares of the biotechnology company’s stock, valued at approximately $11,306,000.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC raised its holdings in Corcept Therapeutics by 1.3% in the third quarter. Quadrant Capital Group LLC now owns 14,007 shares of the biotechnology company’s stock worth $1,650,000 after purchasing an additional 178 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in Corcept Therapeutics by 1.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 10,617 shares of the biotechnology company’s stock valued at $923,000 after buying an additional 184 shares during the period. State of Wyoming lifted its position in Corcept Therapeutics by 29.5% during the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 186 shares during the period. Wedmont Private Capital boosted its holdings in shares of Corcept Therapeutics by 6.1% during the 3rd quarter. Wedmont Private Capital now owns 3,329 shares of the biotechnology company’s stock valued at $395,000 after buying an additional 190 shares in the last quarter. Finally, Choreo LLC boosted its holdings in shares of Corcept Therapeutics by 8.0% during the 3rd quarter. Choreo LLC now owns 4,190 shares of the biotechnology company’s stock valued at $483,000 after buying an additional 312 shares in the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on CORT shares. Weiss Ratings raised shares of Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. Wall Street Zen raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Zacks Research cut shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective on the stock. in a research note on Monday, July 27th. Finally, HC Wainwright restated a “buy” rating and issued a $165.00 price objective on shares of Corcept Therapeutics in a report on Friday, September 18th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $139.50.
Read Our Latest Research Report on CORT
Corcept Therapeutics Price Performance
CORT stock opened at $72.94 on Monday. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $126.38. The firm has a market cap of $7.98 billion, a PE ratio of 57.43 and a beta of 0.54. The business has a 50 day moving average of $103.70 and a 200 day moving average of $76.43.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.17. Corcept Therapeutics had a return on equity of 22.56% and a net margin of 16.53%. The business had revenue of $340.47 million during the quarter, compared to analysts’ expectations of $339.12 million. During the same quarter in the previous year, the business earned $0.16 earnings per share. The firm’s quarterly revenue was up 64.0% compared to the same quarter last year. On average, research analysts expect that Corcept Therapeutics Incorporated will post 1.97 earnings per share for the current fiscal year.
Insider Transactions at Corcept Therapeutics
In other news, Director James Wilson sold 10,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $114.81, for a total transaction of $1,148,100.00. Following the completion of the transaction, the director directly owned 1,054,543 shares in the company, valued at $121,072,081.83. This trade represents a 0.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Swisher, Jr. sold 1,500 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $74.07, for a total value of $111,105.00. Following the transaction, the director owned 1,100 shares of the company’s stock, valued at $81,477. The trade was a 57.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 353,041 shares of company stock valued at $40,016,889. 20.70% of the stock is currently owned by corporate insiders.
About Corcept Therapeutics
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Further Reading
- Five stocks we like better than Corcept Therapeutics
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
